Management of cardiorenal syndrome in heart failure

Current Cardiology Reports

Volumn 8, Issue 3, 2006, Pages 211-216

  Patel, Jigar ^a   Heywood, J Thomas ^b  

^a SCRIPPS CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; HYPERTENSIVE AGENT; INOTROPIC AGENT; LEVOSIMENDAN; NESIRITIDE; NITROPRUSSIDE SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT;

ANGIONEUROTIC EDEMA; CLINICAL TRIAL; COUGHING; DISEASE EXACERBATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FLUID THERAPY; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART ASSIST DEVICE; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY PERFUSION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PROGNOSIS; RENAL REPLACEMENT THERAPY; RENOVASCULAR DISEASE; REVIEW; SURVIVAL RATE;

HEART FAILURE, CONGESTIVE; HUMANS; PROGNOSIS; RENAL INSUFFICIENCY; SYNDROME;

EID: 33646436489     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-006-0036-8     Document Type: Review

References (38)

1. Levy D, Kenchaiah S, Larson MG, et al.: Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002, 347:1397-1402.
2. Roger VL, Weston SA, Redfield MM, et al.: Trends in heart failure incidence and survival in a community-based population. JAMA 2004, 292:344-350.
3. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
4. CIBIS-II Investigators and Committees: The Cardiac Insufficiency and Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13.
5. Poole-Wilson PA, Swedberg K, Cleland JG, et al., Carvedilol Or Metoprolol European Trial investigators: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362:7-13.
6. Hardy GH, Lee KL, Mark DB, et al., Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) investigators: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352:225-237.
7. American Heart Association: Heart Disease and Stroke Statistics - 2005 Update. Dallas: American Heart Association; 2005.
8. Meguid El Nahas A, Bello AK: Chronic kidney disease: the global challenge. Lancet 2005, 365:331-340.
9. Heywood JT: The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev 2004, 9:195-201.
10. Hillege HL, Girbes AR, de Kam PJ, et al.: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000, 102:203-210.
11. The SOLVD investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
12. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
13. Levey AS, Bosch JP, Lewis JB, et al.: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
14. Fonarow GC, Adams KF, Abraham WT, ADHERE investigators: Risk stratification for in-hospital mortality in heart failure using classification and regression tree (CART) methodology: analysis of 33,046 patients in the ADHERE registry [abstract 290]. J Card Fail 2003, 9(Suppl):S79.
15. Gottlieb SS, Abraham W, Butler J, et al.: The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002, 8:136-141.
16. Heywood JT, Elatre W, Pai RG, et al.: Simple clinical criteria to determine the prognosis of heart failure. J Cardiovasc Pharmacol Ther 2005, 10:173-180.
17. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 2001, 345:588-595.
18. Schrier RW, Abraham WT: Hormones and hemodynamics in heart failure. N Engl J Med 1999, 341:577-585.
19. Ljungman S, Laragh JH, Cody RJ: Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs 1990, 39(Suppl 4):10-21.
20. Blake WD, Wegria R, Keating RP, Ward HP: Effect of increased renal venous pressure on renal function. Am J Physiol 1949, 157:1-13.
21. Burnett JC Jr, Knox FG: Renal interstitial pressure and sodium excretion during renal vein constriction. Am J Physiol 1980, 238:F279-F282.
22. Doty JM, Saggi BH, Sugerman HJ, et al.: Effect of increased renal venous pressure on renal function. J Trauma 1999, 47:1000-1003.
23. Firth JD, Raine AE, Ledingham JG: Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet 1988, 1:1033-1035.
24. Cody RJ, Ljungman S, Covit AB, et al.: Regulation of glomerular filtration rate in chronic congestive heart failure patients. Kidney Int 1988, 34:361-367.
25. Packer M, Lee WH, Medina N, et al.: Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987, 106:346-354.
26. Harris PJ, Navar LG: Tubular transport response to angiotensin. Am J Physiol 1985, 248:F621-F630.
27. Weinfeld MS, Chertow GM, Stevenson LW: Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 1999, 138:285-290.
28. Publication Committee for the VMAC investigators (Vasodilatation in the Management of Acute CHF): Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002, 287:1531-1540.
29. Butman SM, Ewy GA, Standen JR, et al.: Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest or inducible jugular venous distension. J Am Coll Cardiol 1993, 22:968-974.
30. Costanzo MR, Saltzber M, O'Sullivan J, Sobotka P: Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol 2005, 46:2047-2051.
31. Rimondini A, Cipolla CM, Della Bella P, et al.: Hemofiltration as short-term treatment for refractory congestive heart failure. Am J Med 1987, 83:43-48.
32. Friedrich JO, Adhikari N, Herridge MS, Beyene J: Metaanalysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005, 142:510-524.
33. Stevenson LW: Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: Inotropic infusions during hospitalizaiton. Circulation 2003, 108:367-372.
34. Slawsky MT, Colucci WS, Gottlieb SS, et al.: Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000, 102:2222-2227.
35. Argenziano M, Choudhri AF, Oz MC, et al.: A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997, 96(9 Suppl):II-286-II-290.
36. Rose EA, Gelijns AC, Moskowitz AJ, et al., Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001, 345:1435-1443.
37. Keane WF: Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis 2000, 35: S97-S105.
38. Suki WN: Renal hemodynamic consequences of angiotensin-converting enzyme inhibition in congestive heart failure. Ann Intern Med 1989, 149:669-673.